Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 1,429 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: opiates Clear all

Conditions: Lumbar Disc Herniation, Degenerative Disc Disease, Spondylolisthesis
Interventions: Morphine, Epinephrine, naropin; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Intra-abdominal Cancer
Interventions: Hydrocodone, Tramadol, Oxycodone; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pharmacodynamic
Interventions: Nalmefene hydrochloride, Naloxone hydrochloride; Drug
Lead sponsor: Opiant Pharmaceuticals Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Lichen Planopilaris, Frontal Fibrosing Alopecia
Interventions: Low-Dose Naltrexone; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Hernia, Abdominal, Pain
Interventions: acetominophen, ibuprofen, oxycodone, Oxycodone; Drug
Lead sponsor: Khashayar Vaziri; Other
Eligibility: 18 Years to 90 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Opioid Use Disorder
Interventions: Naltrexone, Placebo, Buprenorphine; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 9
States / cities: Lauderhill, Florida • Oakland Park, Florida • Winfield, Illinois + 6 more

Conditions: Adenotonsillectomy, Post-operative Analgesia, Opioid Use
Interventions: Oxycodone, Ibuprofen, Acetaminophen, Opioid disposal pouch, Opioid disposal education; Drug · Other
Lead sponsor: David Chi, MD; Other
Eligibility: 3 Years to 17 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Atopic Dermatitis, Pruritus, Pruritus Chronic, Dermatitis
Interventions: Naltrexone, Placebo; Drug · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Binge Drinking, HIV
Interventions: Placebo, Naltrexone, Medical Management (MM) counseling for alcohol use:, Urinalysis for novel alcohol biochemical markers:, Behavioral survey measurements:, Dried Blood Spot (DSB) Testing for Phosphatidylethanol, Ecological Momentary Assessment; Drug · Behavioral · Diagnostic Test
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 70 Years · Male only
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Pain
Interventions: Naltrexone, then placebo, Placebo, then Naltrexone; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 40 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Chronic Pain
Interventions: Pregabalin, Placebo; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Opioid Dependence
Interventions: Buprenorphine; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Chronic Noncancer Pain
Interventions: oxycodone HCl and naltrexone HCl extended-release capsules; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 395 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 32
States / cities: DeLand, Florida • Jacksonville, Florida • Jupiter, Florida + 27 more

Conditions: Obsessive-Compulsive Disorder
Interventions: Fluoxetine 60 mg, Naltrexone 32 mg and fluoxetine 60 mg, Naltrexone SR 32 mg; Drug
Lead sponsor: Orexigen Therapeutics, Inc; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 11
States / cities: National City, California • San Diego, California • Gainesville, Florida + 8 more

Conditions: Pectus Excavatum
Interventions: Hydromorphone, Morphine; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 8 Years to 18 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Infections, Opioid Use Disorder, Incarceration; Lens
Interventions: Cabotegravir Injection, Cabotegravir Pill, Buprenorphine injection, Buprenorphine Pill; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Agitation Associated With Alzheimer's Disease Dementia
Interventions: EXV-802, Placebo, EXV-801; Drug
Lead sponsor: Exciva GmbH; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 9
States / cities: Murrieta, California • Indianapolis, Indiana • Flowood, Mississippi + 6 more

Conditions: Opioid-induced Constipation
Interventions: Methylnaltrexone Bromide, Placebo-Normal Saline; Drug
Lead sponsor: St. John Health System, Michigan; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Southfield, Michigan

Conditions: Major Depressive Disorder, Depression
Interventions: venlafaxine XR, buprenorphine, Placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 50 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Fracture
Interventions: Buprenorphine 0.15 MG, Hydromorphone 0.25 mg IV; Drug
Lead sponsor: Cooper Norcross Health; Other
Eligibility: 65 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Camden, New Jersey

Conditions: Amphetamine-Related Disorders
Interventions: Naltrexone, Placebo; Drug
Lead sponsor: San Francisco Department of Public Health; Government
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Chronic Pain
Interventions: Hydrocodone Bitartrate; Drug
Lead sponsor: Zogenix, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 424 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 50
States / cities: Phoenix, Arizona • Sierra Vista, Arizona • Little Rock, Arkansas + 44 more

Conditions: Chronic Non-malignant Pain
Interventions: Buprenorphine transdermal patch, Placebo to match BTDS; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 18 Years and older
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001
U.S. locations: 21
States / cities: Phoenix, Arizona • Trumbull, Connecticut • Clearwater, Florida + 17 more

Conditions: Idiopathic Intracranial Hypertension
Interventions: Acetazolamide, Placebo, Formal weight loss counselling program; Drug · Behavioral
Lead sponsor: St. Luke's-Roosevelt Hospital Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 39
States / cities: Birmingham, Alabama • Los Angeles, California • Waterbury, Connecticut + 31 more

Search by objective public record fields.

Peri-Incisional Drug Injection in Lumbar Spine Surgery

5x-Multiplier vs 3-Tier Model for Discharge Opioid Prescriptions After Intra-abdominal Cancer Surgery: A Randomized Clinical Trial

Pharmacodynamic Evaluation of Intranasal Nalmefene

Oral Low-Dose Naltrexone for Lichen Planopilaris and Frontal Fibrosing Alopecia

Multimodal Pain Therapy After Hernia Repair

Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL

Non-Opioid Pain Medications After Intracapsular Adenotonsillectomy

Treatment of Chronic Itch in Atopic Dermatitis With Opioid Antagonist Naltrexone

Better Than Study: Targeting Heavy Alcohol Use With Naltrexone Among Men Who Have Sex With Men (MSM)

Attenuation of Pain in Men and Women

Increased Sensitivity to Pain Caused by Opioids in People Who Have Abused Prescription Opioids

Buprenorphine Treatment for Opioid Dependence

Safety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Noncancer Pain

Naltrexone SR and Fluoxetine Combination Therapy in Subjects With Obsessive-Compulsive Disorder

A Comparison Trial Between PCA and Epidural Analgesia for Pectus Excavatum Repair

NOTRE: Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral Settings

Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia

Methylnaltrexone for Treatment of Opiate-Induced Constipation in the Intensive Care Unit

Buprenorphine Used With Treatment Resistant Depression in Older Adults

Buprenorphine for Analgesia in Older Adults With Acute Fractures in the Emergency Department

Extended-Release Naltrexone to Treat Methamphetamine Dependence in Men Who Have Sex With Men (MSM)

Long-Term Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Pain

Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Nonmalignant Pain

Idiopathic Intracranial Hypertension Treatment Trial